New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication.
Methods
In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were used as the in vitro and in vivo models to evaluate the anti-HBV activity of FNC.
Results
In the cell model, FNC effectively suppressed the secretion of the HBV antigens in a dose-dependent manner, with 50% effective concentration values of 0.037 μM for hepatitis B surface antigen and 0.044 μM for hepatitis B e antigen on day 9. Consistent with the HBV antigen reduction, FNC also reduced the HBV DNA level by 92.31% and 93.90% intracellularly and extracellularly, respectively. DHBV DNA levels were markedly reduced after treatment with the FNC at 0.5, 1.0 and 2.0 mg/kg•day dosages. The inhibition rate of FNC at the dose of 2.0 mg/ kg•day reached 91.68% and 81.96%, in duck serum and liver, respectively, on day 10. Furthermore, significant liver histology restoration after FNC treatment was observed, as evaluated by the histopathological analysis.
Conclusions
FNC can evidently inhibit the replication of HBV in the HepG2.2.15 cell line in vitro and inhibits DHBV replication in ducks in vivo. It could be potentially developed into a new anti-HBV drug.
References
1.
SrivastavN.C., ShakyaN., MakM., AgrawalB., TyrrellD.L., KumarR.Antiviral activity of various 1-(2′-deoxy-beta-d-lyxofuranosyl), 1-(2′-fluoro-beta-d-xylofuranosyl), 1-(3′-fluoro-beta-d-arabinofuranosyl), and 2′-fluoro-2′,3′-didehydro-2′,3′-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication. J Med Chem2010; 53: 7156–7166.
2.
FanJ.M., ZhangQ., XuJ.Inhibition on hepatitis B virus in vitro of recombinant MAP30 from bitter melon. Mol Biol Rep2009; 36: 381–388.
3.
TorbensonM., ThomasD.L.Occult hepatitis B. Lancet Infect Dis2002; 2: 479–486.
4.
WuJ.M., LinJ.S., XieN., LiangK.H.Inhibition of hepatitis B virus by a novel l-nucleoside, beta-l-D4A and related analogues. World J Gastroenterol2003; 9: 1840–1843.
5.
DelaneyW.E., MillerT.G., IsomH.C.Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother1999; 43: 2017–2026.
6.
GuoQ., ZhaoL., YouQ.Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res2007; 74: 16–24.
7.
WangQ., LiuX., ZhangY.FNC, a novel nucleoside analogue inhibits cell proliferation and tumor growth in a variety of human cancer cells. Biochem Pharmacol2011; 81: 848–855.
8.
OhruiH., KohgoS., HayakawaH.2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favourable toxic profiles and stability in plasma. Nucleic Acids Symp Ser (Oxf)2006; 50: 1–2.
9.
KlumppK., KalayanovG., MaH.2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem2008; 283: 2167–2175.
10.
GaoL.L., WangX.Y., LinJ.S., ZhangY.H., LiY.Efficacies of beta-l-D4A against hepatitis B virus in 2.2.15 cells. World J Gastroenterol2008; 14: 1263–1267.
11.
JahnB., MartinE., StuebenA., BhakdiS.Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol1995; 33: 661–667.
12.
MosmannT.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods1983; 65: 55–63.
13.
FerrariM., FornasieroM.C., IsettaA.M.MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods1990; 131: 165–172.
14.
PangR., TaoJ., ZhangS.In vitro anti-hepatitis B virus effect of Hypericum perforatum L. J Huazhong Univ Sci Technolog Med Sci2010; 30: 98–102.
15.
LiuY-K, ZhengL., ChangJ-B. Development and application of real-time PCR assay for detection of duck hepatitis B virus. Journal of Yangzhou University (Agricultural and Life Science Edition)2010; 31: 7–12.
16.
LiJ., HuangH., FengM., ZhouW., ShiX., ZhouP.In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L. Antiviral Res2008; 79: 114–120.
17.
GüntherS., LiB.C., MiskaS., KrügerD.H., MeiselH., WillH.A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immonusuppressed patients. J Virol1995; 69: 5437–5444.
18.
MarionP.L., SalazarF.H., WintersM.A., ColonnoR.J.Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother2002; 46: 82–88.
19.
XieH.Y., XiaW.L., ZhangC.C.Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta Pharmacol Sin2007; 28: 975–984.
20.
LiuT., ZhaoJ., LiH., MaL.Evaluation on anti-hepatitis viral activity of Vitis vinifer L. Molecules2010; 15: 7415–7422.
21.
LaiC.L., YuenM.F.Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol2000; 61: 367–373.
22.
HeY.W., GuoC.X., PanY.F., PengC., WengZ.H.Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro. World J Gastroenterol2008; 14: 1592–1597.
23.
LevineS., HernandezD., YamanakaG.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother2002; 46: 2525–2532.
24.
LinM., YangL.Y., LiW.Y., PengY.P., ZhengJ.K.Inhibition of the replication of hepatitis B virus in vitro by oxymatrine. J Int Med Res2009; 37: 1411–1419.
25.
HanY.Q., HuangZ.M., YangX.B., LiuH.Z., WuG.X.In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica. J Ethnopharmacol2008; 118: 148–153.
26.
ZoulimF.Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res1999; 44: 1–30.
27.
SchillerJ.T., LowyD.R.Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol2010; 64: 23–41.
28.
LiC.Q., ZhuY.T., ZhangF.X.Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo. World J Gastroenterol2005; 11: 426–428.
29.
ChuC.K., BoudinotF.D., PeekS.F.Preclinical investigation of l-FMAU as an anti-hepatitis B virus agent. Antivir Ther1998; 3: 113–121.
30.
ChenY.X., HuangA.L., QiZ.Y., ShanY.L., SunH.Assessment of a method for detecting serum HBV DNA with HBV DNA probe labelled directly by alkaline phosphatise. Hepatobiliary Pancreat Dis Int2003; 2: 553–556.
31.
DongB., ShaoX.W., TaoP.Z.Inhibition of duck hepatitis B virus DNA replication by antisense phosphorothioate oligodeoxynucleotides in vitro and in vivo. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi2003; 17: 25–27.
